The research focusses on several aspects related to reimbursement: factors influencing the time to reimbursement, measures to improve the time to reimbursement, differences in the clinical evidentiary requirements of oncology assessment, EMA versus HTA bodies and changes in economic evaluations of oncology drugs in time.
The research project aims to develop models for the prediction of disease duration in order to support personalized and cost-effective care of depression patients. Using these models, optimal treatment strategies will be analyzed. In this project, we also want to predict treatment resistant depression as a specific subgroup and conduct cost-effectiveness analyses of different psychotherapy strategies and quantify the impact of structural uncertainty and parameter uncertainty on the results of cost-effectiveness evaluations.
Economische aspecten van gepersonaliseerde hart- en vaatziektepreventie bij personen met type 2 Diabetes Mellitus.
Onderzoek naar de economische waarde van nieuwe longkanker- en ILD-geneesmiddelen.
The aim is to present current and new strategies university hospitals can undertake to contain costs of expensive drugs using a drug life cycle approach.
To explore and implement strategies for optimizing healthcare resource utilization in oncology, with the aim of advancing the (financial) sustainability in oncology care.